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Abstract: Mesenchymal stem cells (MSCs) can differentiate into multiple different tissue lineages
and have favourable immunogenic potential making them an attractive prospect for regenerative
medicine. As an essential part of the manufacturing process, preservation of these cells whilst
maintaining potential is of critical importance. An uncontrolled area of storage remains the rate of
change of temperature during freezing and thawing. Controlled-rate freezers attempted to rectify
this; however, the change of phase from liquid to solid introduces two extreme phenomena; a rapid
rise and a rapid fall in temperature in addition to the intended cooling rate (normally −1 ◦C/min) as a
part of the supercooling event in cryopreservation. Nucleation events are well known to initiate the
freezing transition although their active use in the form of ice nucleation devices (IND) are in their
infancy in cryopreservation. This study sought to better understand the effects of ice nucleation and
its active instigation with the use of an IND in both a standard cryotube with MSCs in suspension and
a high-throughput adhered MSC 96-well plate set-up. A potential threshold nucleation temperature
for best recovery of dental pulp MSCs may occur around −10 ◦C and for larger volume cell storage,
IND and fast thaw creates the most stable process. For adhered cells, an IND with a slow thaw
enables greatest metabolic activity post-thaw. This demonstrates a necessity for a medical grade IND
to be used in future regenerative medicine manufacturing with the parameters discussed in this study
to create stable products for clinical cellular therapies.
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1. Introduction
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into multiple
different tissue lineages [1] making them an attractive prospect for regenerative medicine. However,
a potentially more accessible application lies with their immune-modulatory activities and beneficial
paracrine interactions [2]. MSCs can be isolated from many sources, including bone marrow and
adipose tissue [3]. Dental pulp, from surplus extracted teeth, is a good source of highly proliferative
MSCs without the technical limitations of other tissues. MSCs possess a multi-lineage differentiation
capability and immunomodulation effect through production of molecules such as PGE2, IL-6 and nitric
oxide. Through these mechanisms, MSCs have demonstrated possible positive effects against human
age-related diseases [4] and have already reached the clinic for diseases like Alzheimer’s [5]. Minimal
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criteria to characterize MSCs were laid out by the International Society for Cellular Therapies (ISCT) in
2006 including, plastic adherence, tri-lineage differentiation (osteoblast, adipocyte, chondroblast) and
positivity for surface markers of CD90, CD105 and CD73. CD 14, CD34 and CD45 must also be lacking
expression in MSCs.
For commercial viability and patient access, it is necessary to have efficient, consistent, long term
storage of MSCs. This will enable greater flexibility for storage and transport, and reduce costs of
production through large batch manufacturing. Long term storage generally occurs at temperature
less than −135 ◦C [6]. Yet, this cryopreservation can alter MSC function and consequently may lose
their therapeutic potential [7,8]. There are several factors that interfere with cryopreservation, such as
fluctuation in the temperature of ice nucleation, inadequate cryopreservation agent concentrations
and thawing rate [9]. This can lead to cellular damage from osmotic imbalance, lethal intracellular ice
formation, exposure to toxic concentrations of cryoprotective agents during freezing and oxidative
stress during thawing (potentially as a result of osmotic imbalances) and after. These effects are felt
within the first 36 h of culture following thaw. Further reading on cryopreservation stress factors and
their resulting effects were discussed by Baust et al. (2009) [10]. It is therefore vital to improve the
cryopreservation process to reduce variability and negative MSC population function effects.
As one of the greatest influencers in freezing rate instability, ice nucleation is characterized by the
change in state of the cryosolution from liquid to solid [11]. As the temperature of the cell suspension
reduces, latent heat in the system allows the solution to remain liquid below the freezing point of
water. At a certain temperature defined by the roughness of the cryovessel surface and salt content and
disturbances in the cryosolution, the phase change happens [12–15]. During this stochastic process,
energy, in the form of heat, is released, causing a rapid rise in temperature back towards 0 ◦C, followed
by a rapid reduction [13,16]. The lower the temperature of ice nucleation occurs, the greater the
change in the rate of cooling. Ice seeding (the addition of components to induce ice nucleation)
has demonstrated the potential to induce ice formation at temperatures greater than −10 ◦C which
could reduce the chaotic effects during freezing and allow for a better controlled manufacturing
process [13,17–21].
A less controlled area of cryopreservation is the thawing rate. It is widely assumed that a fast
thawing rate (less than 5 min) reduces the chances of localized re-freezing causing damage to the
cells [22]. Conventional procedure is to use a water bath in which user/protocol variability has a
large influence on cell viability. Recently, in tandem with controlled rate freezers, controlled rate
thawing has been applied to cryovials and cryobags when considering cells for use in therapies,
although the accepted thawing rate is still high. While this has now been applied to testicular
interstitial cells, pluripotent and mesenchymal stem cells [23,24] frozen in cryovials, there are no data
on cryopreservation of MSC in a 96-well plate format. This could be used in developing cryosolutions
or as a pre-prepared plate for toxicology testing or rapid distribution of cells. This manuscript seeks to
enhance our understanding of the effects of using (1) a new ice seeding device, (2) plate freezing of
adhered cells and (3) thawing rates, on cell viability, metabolic activity and differentiation capability as
part of a wider manufacturing process.
2. Results
2.1. Ice Nucleation Temperature
Changes in the temperature of ice formation due to the inclusion of an ice nucleator were
measured during controlled rate freezing at 1 ◦C/min. In cryovials with 1.0 mL of cryostorage solution,
a characteristic spike in the solution temperature, associated with the change in phase, was observed
over a range of approximately 7 ◦C from −9.7 ◦C to −16.5 ◦C. This resulted in a maximum cooling
gradient of−2.64± 0.67 ◦C/min to return to the continuing 1 ◦C/min (Figure 1A). A slight deviation from
the intended cooling rate in addition to the effects of the phase change is observed from inefficiencies
in the sterling engine heat transfer as the differential in internal and ambient temperature increase.
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With the inclusion of an ice nucleator, the mean nucleation temperature is increased significantly to
a range of −5.9 ◦C to −9.4 ◦C with a reduced standard deviation (Figure 1B). This also results in a
reduced max cooling rate of −2.16 ± 0.05 ◦C/min with an accompanying 10-fold reduction in coefficient
of variation over the IceStart− condition.
Figure 1. Freezing profiles and nucleation temperature. (A) Cryovial cryosolution temperature change
over time with (orange) and without (blue) an ice nucleation device (IND). (B) Nucleation temperature
of cryosolution in different conditions (IND+/-) in both 96-well plates and cryovials. (C) The 96-well
plate cryosolution temperature variation over time IND+: Orange, IND-: Blue. (D) Cryosolution
nucleation temperature variation due to well distance from edge IND+/-. (Vials: n = 4 replicates + 3
repeats per condition. 96-well plates: n = 4 repeats of three well positions. * p ≤ 0.05, *** p ≤ 0.001,
bars represent ± SD).
In 96-well plates, the cooling profiles demonstrate an initial spike in temperature before decreasing
rapidly towards the 1 ◦C/min cooling rate, followed by a secondary thermal instability at approximately
−20 ◦C (Figure 1C). Inclusion of the ice nucleation device (IND) into the wells significantly increased
(p < 0.001) the ice formation temperature (Figure 1B) from −11.57 ± 1.39 ◦C to −5.01 ± 2.18 ◦C.
Interestingly, the variation in the 96-well plate normal conditions (IceStart−) were lower than in vials
without an IND and, in contrast to the cryovials, variation was increased in the 96-well plates with the
addition of the IND. Cooling in the controlled-rate freezer is done by direct contact with a cold plate
and conducting surface to the wells; in 96-well plates, no significant differences were observed in well
position in IceStart− conditions (Figure 1D). With the addition of the IND, those wells closer to the
edge of the plate had a significantly higher temperature of ice formation. This is possibly due to the
overall increased mass with the addition of the device, and therefore an increase in the latent heat to be
removed for each well closer to the centre of the plate. Despite an increased variation with an IND,
the maximum cooling rate is significantly reduced (p < 0.001) from −5.73 ± 1.07 ◦C/min (IceStart−)
to −2.57 ± 1.12 ◦C/min, although the range remains approximately consistent regardless of the mean
shift (IceStart−: −7.6 to −4.2 ◦C/min, IceStart+: −5.4 to −1.6 ◦C/min). It is important to note that the
nucleation temperature is significantly increased with the addition of the IND despite the presence of
the thermocouples which act as an additional source of ice nucleation.
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2.2. Effect of Thawing with Ice Nucleation Device
Thawing rates were also investigated to ascertain whether overall rate of temperature change,
timing of phase change or time from 0 ◦C were affected by the IND (Figure 2). A cell culture incubator
set to 37 ◦C was used as a slower method of thawing (warming from ambient temperature) and the
heating function of the controlled rate freezer at 37 ◦C as a fast thawing method. Within the cryovials,
the extra mass of the IND only altered the heating time significantly from 0–25 ◦C with ambient heating
in the incubator. This difference, whilst statistically significant, can be considered negligible with only
a 14.83 s difference. Contrastingly, the increased mass of the IND array in the 96-well plates caused a
significant difference in time to 0 ◦C and a large difference in the means over the phase transition (−5 to
5 ◦C). The variability, potentially due to the well position, renders this difference to be not statistically
significant (p = 0.097).
Figure 2. Thawing profiles and time across significant temperature zones. Vial (A) and 96-well plate
(B) cryosolution temperature during warming (fast warming provided by ViaFreeze device, slow
warming provided by incubator). Slow thaw/IND-: Blue, Slow thaw/IND+: Red, Fast thaw IND-: Green,
Fast thaw IND+: purple (C,D) Time from long-term storage temperature to theoretical melting point.
(E,F) Time from theoretical melting point to room temperature towards acceptable culture temperature.
(G,H) Time across phase change temperature range—solid to liquid. (n = 2 replicates + 3 repeats for
each condition * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, bars represent ± SD). Legend applies
to both graphs on row.
In line with this significant increase in nucleation temperature with an IND, viability, as measured
by membrane integrity, was significantly greater (p ≤ 0.05) in IceStart+ conditions (Figure 3). The slow
thaw (ST) conditions had a significantly reduced viability in comparison to the more standard fast thaw
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(FT) conditions; although, the IND demonstrates a similar result to the fast thaw IceStart− conditions.
This suggests that the less variable cooling may help to ensure membrane integrity and assists in the
controlled nature of the thaw. In terms of variability, ST IceStart− conditions demonstrated the greatest
proportional variation (coefficient of variation) with no other significant differences occurring.
Figure 3. Mesenchymal stem cell (MSC) recovery characteristics using IND+/-, Slow Thaw (ST) and
Fast Thaw (FT) conditions. (A) Viability measured through membrane integrity at thaw in vials.
(B,D,F,H,J) corresponding coefficient of variation. (C) Viability at first passage following thaw in vials.
(E) Population doublings after 1 passage from cryostorage in vials. Metabolic activity at four days
(passage 1) following thaw in vials (G) and 96-well plates (I). (Vials—n = 6 replicates + 3 donor repeats
for each condition. 96-well plates—n = 48 replicates + 3 donor repeats for each condition. * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001, bars represent ± SD).
After one passage, although the fast thaw conditions were significantly greater (p ≤ 0.001),
all conditions had a viability greater than 95%. A similar relationship is again observed in each donor
and no significant differences in variation. However, in cell number, IceStart+ FT conditions had a
greater mean yield although the variation across all other condition suggests that this is not significant.
Between IceStart+ ST and IceStart− FT, cell numbers were not significantly different again suggesting
that the IND may be causing greater variation in the cryopreservation process. However, slow thaw
conditions appear to negatively affect the metabolic activity of the cell populations with IceStart+ ST
conditions affected the most (Figure 3G). This may be a consequence of a slower thaw causing osmotic
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imbalances. Despite no significant differences, the metabolic activity associated co-efficient of variation
was also lowest in the IceStart+ FT conditions.
In 96-well plate conditions, where the cells are attached prior to freezing, ST conditions had
significantly greater metabolic activity. IceStart+ conditions demonstrated approximately double the
metabolic activity of their IceStart− counterparts but IceStart+ ST was only approximately 40% of the
no freeze controls. This substantial difference is most likely attributed to changes in the plate surface
(size and mechanical properties) which caused cell detachment and potentially damage. Unlike in
vial recovery conditions, the greatest co-efficient of variation associated with metabolic activity was in
the IceStart+ FT conditions; however, this is most likely due to the very low recovery in the IceStart−
FT condition.
A total of 24 h after thawing in 96-well plates, similar metabolic activity was observed in both
slow and fast thaw conditions (Figure 4) although in fast thaw conditions, greater activity is observed
in the IceStart− (IS- FT) condition than in the IS- ST. No significant well position bias (Figure 5) is
apparent although the no freeze control suggests a slight reduction in metabolic activity towards the
centre of the plate (Figure 5E). This shows that despite a significant difference in well position and
the temperature of ice nucleation across a plate (Figure 1D), this has no effect on the recovery of the
cells, potentially indicating a threshold nucleation temperature for best recovery of dental pulp MSCs
around −10 ◦C. A reduction in metabolic activity across the four days, in some wells of the FT IS-
condition, indicates that damage is occurring as a result of the thawing. With the combination of IS+
and slow thaw demonstrating greatest recovery in continued culture, the IND may offer protection
during the freezing process. This is possibly due to minimized possibility of temperature gradients in
a small volume of medium. A slower thaw may then cause the expansion rate of the culture surface to
happen over a longer time period (as a solid, warming at a different rate to the liquid), enabling the
cell to adjust.
Figure 4. Metabolic activity normalised to Day 1 No Freeze control values for each well, respectively.
IceStart+ conditions demonstrate greater metabolic activity following thaw with slow thaw conditions
recovering to the greatest extent. n = 3 donor repeats. (A) Day 1 post thaw MTT slow thaw, (B) Day 4
slow thaw, (C) fast thaw Day 1, (D) Day 4 fast thaw, (E) Day 4 equivalent No Freeze control. n = 3
donor repeats for each condition.
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Figure 5. Linear regression with 95% confidence intervals of Day 4 metabolic activity (normalised to
Day 1 No Freeze control values for each well respectively). (A) IceStart+ slow thaw (ST), (B) IceStart−
ST, (C) IceStart+ fast thaw (FT), (D) IceStart− FT, (E) No Freeze control. Frequency of well position
values vary due to different replicate positions across a 96-well plate. Mean values calculated from
n = 3 donor repeats for each well position.
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2.3. Differentiation Ability of MSC after Freezing with IceStart
Following differentiation protocols for vial conditions to ensure that the IND had no negative
effects on the functionality of the MSCs, osteogenic, chondrogenic and adipogenic differentiation was
observed (Figures 6 and 7). The IceStart had no negative effect on the differentiation ability of the MSC.
Figure 6. Representative images of MSC tri-lineage differentiation. No inhibition of differentiation was
observed in any condition (3 donors). Control is stain control (without culture in differentiation medium).
Osteogenic and chondrogenic conditions scale bar: 100 µm, Adipogenic conditions scale: 50 µm.
Int. J. Mol. Sci. 2020, 21, 8579 9 of 16
Figure 7. Quantitative analysis of osteogenic and chondrogenic differentiations. All differentiation
conditions significantly greater than no differentiation controls with no significance between conditions.
(** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, bars represent ± SD n = 3 replicates + 3 donor repeats
per condition.
3. Discussion
Cryopreservation is an important part of any cell therapy supply chain, for both commercial
and research purposes. With the potential positive effects of especially allogeneic MSCs in many
different diseases, effective long-term storage is critical. Current cryopreservation methods store
cells in suspension in cryopreservation solutions below −135 ◦C [6]. The process of cooling and
thawing, as well as the influence of the cryopreservation agents, can lead to damage and alteration of
the desired function of the MSCs [7,8]. Cooling rate is one of the largest influencers in a successful
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cryopreservation process; freezing at a rate that is considered too slow causes dehydration of the cell
with associated stresses and increases the osmotic imbalances as the solutes are excluded from the
ice crystals potentially exposing cells to toxic concentrations, although the possibility of intracellular
ice is reduced [6,22,25]. This can also lead to oxidative stress through reactive oxygen species (ROS)
overwhelming the antioxidant mechanisms within cells, resulting in molecular damage to DNA,
proteins and lipids [26]. Further, this can result in release of apoptogenic factors which can eventually
lead to cell death. With freezing that is too rapid, osmolality is more balanced but intracellular
ice is increased. Generally, a uniform cooling rate of −1.0 ◦C/min is accepted as effective for most
cells, although exceptions exist [27]. Within the cooling process, variations in the temperature of ice
formation, due to the stochastic nature of supercooling, can cause rapid fluctuations in the cooling rate
from latent heat energy release; the lower the nucleation temperature, the greater the rate of change.
The effect of an inappropriate basic cryopreservation process is normally observed within the first 36 h
following thaw [10].
In the delivery of bespoke or commercialized therapies, a reduction of variations in the
cryopreservation process (freezing and thawing) will reduce overall manufacturing costs and dosages by
enabling a greater yield of functional cells at patient exposure. Additionally, the use of high-throughput
methods (96+ well plates) in cell exposure testing (for example, in drug or CPA discovery) would
benefit from off-the-shelf platforms with cells already attached and ready for culture. Exposure to
rapid changes in temperature can stress cells and result in changes in material properties causing
damage and detachment to cell populations [28].
Ice nucleation occurs from rough surfaces, storage solutions impurities (such as salts) and physical
disturbances in the storage solution. By positively controlling ice formation temperature, cell recovery
may be enhanced by reducing the variation in the rate of change of temperature during cooling and
improve cell recovery and survival. Previous literature has reported spontaneous ice nucleation
occurring at around −10 ◦C in cryovials up to 5.0 mL [29–31], in droplet freezing studies [32] and
in plant sample studies [16]. This is corroborated by the data shown here in which the conditions
without an IND in both 1.8 mL cryovials and in 96-well plates exhibited ice nucleation below −8.9 ◦C
regardless of liquid volume. In the literature, a number of different methods are used to induce ice
formation [11–13,15,33–38]. Many of these methods are unsuitable for use with advanced therapy
medicinal products (ATMPs) as they are non-sterile, labour or cost intensive or would result in damage
to the cells by other means.
Once methods of active induction of ice nucleation were employed in both cryovessels here, ice
nucleation was induced at a significantly higher temperature resulting in more stable cooling rates.
However, the exact nature of the cooling had different characteristics for 96-well plates and cryovials,
despite previous reports of only a weak correlation between volume and nucleation properties [13].
Within cryovials, the addition of the IND resulted in a 10-fold decrease in variation. Contrastingly,
the nucleation temperature range within the plates remained constant despite the IND. A similar result
was reported when using the Snomax ice nucleating agent in which the uniformity of ice nucleation did
not change [33]. Cambell and Brockbank (2014) also report that larger volumes enable more consistent
cooling at slower rates [33].
Additionally, whilst individual wells in a 96-well plate act as isolated cryovessel in biological
terms, they have demonstrated effects from a shared thermal environment which is exacerbated by the
addition of the IceStart Array; well position had a significant effect on the ice nucleation temperature.
This effect is of no surprise considering the increased mass surrounding each well, increasing the latent
heat of the system [39]. Despite this, no significant well position effects were observed in cell recovery
indicating a variable nucleation temperature is not necessarily as important as the temperature above
which ice formation occurs.
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Standard practice for cell recovery in cryovials is to encourage fast thawing utilizing a 37 ◦C
water bath [23,24,35,40]. However, optimal heating rates within 96-well plates have yet to be defined.
In addition to the IND, two thawing rates were investigated with both vials and plates in this study;
fast thawing at 37 ◦C using the controlled rate freezer’s heating function in direct contact with the
contact plate; and slow thawing in a cell culture incubator with the ambient temperature set to 37 ◦C.
As supported by the initial human osteosarcoma cell line (SAOS-2) cells work using IceStart Arrays
in 96-well plates [41], recovery was enhanced with the use of an IND. The slower thaw condition
demonstrated the greatest recovery although the IND enabled the fast thaw condition to have a
similar recovery to slow thaw IND- conditions. Analysis of viability on thaw and after one passage as
well as the population doublings at passage 1 (Day 4) in vials also demonstrates an enhancement in
recovery in 1.8 mL cryovials. Similarly to the 96-well plate condition, the IND was able to compensate
for a less optimal thawing rate. Viability at thaw was greatest in the FT IND+ conditions, but FT
IND- conditions and ST IND+ conditions demonstrated no significant differences, further suggesting
that the use of IceStart in the cryopreservation process is capable of compensating for sub-optimal
cryopreservation processes.
Campbell and Brockbank (2014) also investigated thawing rates in 96-well plate cryopreservation
and 23 ◦C ambient temperature until −20 ◦C then rapid thawing at 37 ◦C [33]. The plates were then
transferred to ice for washing before standard culture. Comparisons between the results of that study
and the results presented here are difficult due to the relative presentation of the data, however the
processes and tools presented in this study are less labour intensive. Campbell and Brockbank did report
that recovery was greatest towards the edges of the plate, in contrast to this study in which recovery
was higher towards the centre in IND+ conditions although as stated, not statistically significant.
Previously reported within the literature, MSC functionality, as measured through tri-lineage
differentiation, has been negatively affected by the cryopreservation process although a recent review
suggested that this trait is often conserved [8]. Utilizing a standard freezing and thawing process
(without an IND and fast thawing in vials), differentiation was not shown to be negatively influenced
in this study, however relatively low repeats may have disguised this. Comparison with the other
conditions (IND+ and fast vs. slow thaw) also shows no difference, although in tandem with reducing
variation in other measurements, it may be that any negative differentiation effects may occur less
often as well.
4. Materials and Methods
4.1. Cell Culture
MSCs were isolated from human dental pulps (ethics approval was given by the ethics committee of
the University of Leipzig, Medical Faculty—Study number 339-13-18112013, according to the Declaration
of Helsinki of 1975. All human donors signed consent forms). Human dental pulp MSCs were expanded
and incubated at 37 ◦C in normoxic conditions (air plus 5% CO2). MSCs were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, 1 g/L D-Glucose, Lonza, Slough, UK) with Glutamax, containing
10% fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Dartford, UK) and experiments were
undertaken between passages 6 to 8 (3 donors, age 18–25 years). Culture medium was exchanged
every two days. MSCs were routinely passaged at 80% confluency by detaching using TrypLE Select
(Gibco, Thermo Fisher Scientific, Dartford, UK) and centrifuging for 5 min (200× g at room temperature).
Live cell numbers were determined using an Acridine Orange (Sigma-Aldrich, Gillingham, UK)
(30 ug/mL)/DAPI (100 ug/mL) solution in dH2O, using the NucleoCounter NC-3000 (ChemoMetec,
Allerød, Denmark). MSC were characterized by FACS for CD90, CD105 and C73 (positive markers)
and CD14, CD20, CD34 and CD45 (negative markers) as well as tri-lineage differentiation before
experimentation (Supplementary Figure S1) as defined by the ISCT [42].
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4.2. Cryopreservation
4.2.1. Freezing Protocol
Freezing of 96-well plates and vials took place in a controlled-rate freezer (ViaFreeze, Asymptote,
Cambridge, UK). The vessels were cooled at 1 ◦C/min until −75 ◦C and then transferred into the vapour
phase of liquid nitrogen (less than −135 ◦C). The chamber of the freezing system (ViaFreeze) was
pre-cooled to 4 ◦C before each experiment (Supplementary Figure S2). Cells were frozen in culture
medium (described above) plus 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, Gillingham, UK)
cryosolution. An experimental schematic is shown in Figure 8.
Figure 8. Experimental design schematic. (A) Cells are placed into vials or seeded into 96-well plates
with cryostorage medium and ice nucleation devices (INDs). The cryovessels are then frozen in a
controlled-rate freezer (CRF) before being transferred to liquid nitrogen (LN2) for extended storage.
The cells were then thawed using either an incubator or the CRF’s heating capability before culturing
and assessment of recovery. (B) Timings schematic for cryostorage culture assessment.
4.2.2. Plates
MSCs were seeded at 4500 cells/well onto tissue culture plastic (polystyrene, Nunclon Delta,
Thermo Fisher Scientific, Dartford, UK) and cultured overnight. Medium was replaced with 100 uL of
cryosolution. A 96-well IceStart array (Asymptote, Cambridge, UK) (Supplementary Figure S2) was
cut in half and placed into 48 wells of the 96-well plate and the plate transferred to freezing conditions.
4.2.3. Vials
Once passaged, the MSCs were suspended in the cryosolution at 1.0 × 106 / mL and then an
IceStart baton was added to the test conditions (Supplementary Figure S2). The vials were then frozen
as described above.
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4.2.4. Thawing Protocol
Frozen vessels were thawed either quickly (fast thaw, less than 8 min using the VIA Freeze)
or slowly (slow thaw, circa. 30 min using an incubator). Following thaw, the IceStart array/baton
was removed and, for 96-well plates, cryomedium replaced with culture medium (described above)
following aspiration. One day post thaw, medium was again exchanged to remove any remaining
traces of cryoprotectant. For vials, the MSC/cryosolution suspension was diluted in culture medium,
centrifuged at 200× g at room temperature for 5 min, viable cells counted as above, resuspended in
culture medium and seeded into 96-well plates at 4500 cells/cm2.
4.3. Cell Recovery (Metabolic Activity)
To assess the effect of position in 96-well plates with and without IceStart, an MTT reduction
assay was performed on separate plates one and four days after thawing. After removal of culture
medium, 100 µL MTT (0.5 mg/mL, Sigma-Aldrich, Gillingham, UK) in culture medium was added to
each well and then left for 3 h at 37 ◦C in normoxic conditions. The supernatant was then removed
leaving the reduced MTT formazan crystals, to which 100 µL DMSO was added to dissolve the crystals.
After 30 min, the 96-well plate was read at 570 nm using a plate reader (FLUOstar Omega BMG
LabTech, Aylesbury, UK) with reference at 630 nm.
To assess cell culture recovery, 100µL of PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific,
Dartford, UK) at 10% v/v dilution in culture medium was added to each well at one- and four-days
post thawing and incubated at 37 ◦C in normoxic conditions for 30 min. The plate was then read at
544 nm/590 nm (Excitation/Emission). For continued culture, the PrestoBlue solution was then replaced
with culture medium.
4.4. Differentiation
Following thaw from vials, the cells were taken through one passage, and then seeded into
relevant plates for quantitative and qualitative differentiation assays. A culture without application of
respective differentiation media before staining provided a negative stain control (referred to as control
in relevant figures).
4.4.1. Osteogenic Differentiation
MSCs were seeded at 10,000 cells/cm2 into a 24-well plate. Medium was changed to osteo-inductive
medium (low-glucose DMEM; 10% FBS; 10 nm dexamethasone, Sigma-Aldrich, Gillingham, UK;
50 µg/mL ascorbic acid 2-phosphate, Sigma-Aldrich, Gillingham, UK). Medium was changed every
2 days for a period of 14 days. For qualitative analysis of osteogenic differentiation, cells were fixed in
70% ethanol for 15 min and washed once with ddH2O. After washing, cells were stained with ALP
buffer at pH 8.5 (0.2 M Tris, 1 mg/mL fast red, Sigma-Aldrich, Gillingham, UK and 50 µg/mL naphthol
phosphate AS-BI, Sigma-Aldrich, Gillingham, UK) for 1 h and imaged under light microscopy.
4.4.2. Adipogenic Differentiation
MSCs were seeded at 20,000 cells/cm2 into a 24-well plate. Cells were then cultured in Adipogenic
medium (10% FBS; 10% insulin-transferrin-selenium supplement, Sigma-Aldrich, Gillingham, UK;
10−8 M dexamethasone, Sigma-Aldrich, Gillingham, UK; 0.5 mM isobutylmethylxanthin, Sigma-Aldrich;
100 µM indomethacin, Sigma-Aldrich, Gillingham, UK). The media was changed every 2 days and
after 14 days cells were analysed by Oil Red O (Sigma-Aldrich, Gillingham, UK) staining and photos
were taken.
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4.4.3. Chondrogenic Differentiation
MSCs were seeded at 50,000 cells/cm2 into a 12-well plate. Cells were then cultured in Chondrogenic
media (10% FBS; 1% pen/strep 1% insulin-transferrin-selenium supplement (Sigma-Aldrich, Gillingham,
UK), 10−7 M dexamethasone (Sigma-Aldrich, Gillingham, UK), 150 µM ascorbic-2-phosphate
(Sigma-Aldrich, Gillingham, UK), 20 µM linoic acid (Sigma-Aldrich, Gillingham, UK) and 0.1 ng/mL
TGF-β (Merck Millipore, Watford, UK). After 2 weeks, cells were stained with Alcian Blue
(Sigma-Aldrich, Gillingham, UK) and photos were taken.
4.5. Temperature Profiles
Freezing and thawing profiles were measured using K-type thermocouples (RS components,
Corby, UK). A TC-08 Thermocouple Data Logger and interface software (PicoLog 4, Pico Technology
Cambridge, UK) were used to record the data.
4.6. Statistics
All experiments conducted with three donors for each assay (replicates stated for each figure).
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, USA). Significant
differences were assessed using a two-way ANOVA with a Bonferroni post-hoc correction for data
with significant F-ratio values. Statistical assumptions were satisfied unless stated otherwise.
5. Conclusions
This study demonstrates the use of a novel sterile, disposable IND for both cryovials and 96-well
plate high-throughput platforms. In both vessels, the IND enhanced recovery and indicated an ability
to compensate for sub-optimal cryopreservation processes. For cryovials, a faster thawing rate with
an IND, resulted in greatest recovery and a reduction in undesirable variation between replicates.
In 96-well plates, a slower thawing rate with an IND is more optimum. With no significant variation
across the plate in cell recovery, this platform represents a viable method for HTS of CPAs and for
delivery of an off-the shelf product for other studies, such as drug discovery.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/22/
8579/s1.
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